SEARCH

SEARCH BY CITATION

References

  • 1
    Nagahara T, Yokoyama Y, Inamura K, Katakura S, Komoriya S, Yamaguchi H, Hara T, Iwamoto M. Dibasic (amidino-aryl) propanoic acid derivatives as novel blood coagulation factor Xa inhibitors. J Med Chem 1944; 37: 12007.
  • 2
    Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994; 71: 3149.
  • 3
    Tanabe K, Terada Y, Shibutani T, Kunitada S, Kondo T. A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor-induced disseminated intravascular coagulation in rats. Thromb Res 1999; 96: 13543.
  • 4
    Hayashi M, Hamada A, Okaya Y, Wakitani K, Aisaka K. Inhibitory effect of JTV-803, a new cyclic guanidine derivative, on factor Xa in vitro and in vivo. Eur J Pharmacol 2001; 428: 1638.
  • 5
    Hayashi M, Matsuo A, Nakamoto H, Aisaka K. Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals. Eur J Pharmacol 2001; 412: 616.
  • 6
    Asakura H, Ichino T, Yoshida T, Suga Y, Ontachi Y, Mizutani T, Kato M, Ito T, Yamazaki M, Aoshima H, Morishita E, Saito M, Miyamoto KI, Nakao S. Beneficial effect of JTV-803, a new synthetic inhibitor of activated factor X, against both lipopolysaccharide-induced and tissue factor-induced disseminated intravascular coagulation in rat models. Blood Coag Fibrinol 2002; 13: 2339.
  • 7
    Yamazaki M, Asakura H, Aoshima K, Saito M, Jokaji H, Uotani C, Kumabashiri I, Morishita E, Ikeda T, Matsuda T. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb Haemost 1994; 72: 3936.
  • 8
    Hara T, Toyoshima A, Tanabe K, Ishihara H, Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, prevents thrombosis without affecting bleeding time in rats. Thromb Haemost 1995; 74: 6359.
  • 9
    Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 1995; 92: 48591.
  • 10
    Huang TF, Sheu JR, Teng CM. A potent antiplatelet peptide, triflavin, from Trimeresurus flavoviridis snake venom. Biochem J 1991; 277: 3517.
  • 11
    Ieko M, Ichikawa K, Triplett DA, Matsuura E, Atsumi T, Sawada K, Koike T. β2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 1999; 42: 16774.
  • 12
    Ibbotson SH, Tate GM, Davies JA. Thrombin activity by intrinsic activation of plasma in vitro accelerates with increasing age of the donor. Thromb Haemost 1992; 67: 37780.
  • 13
    Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surface. J Biol Chem 1991; 266: 73538.
  • 14
    Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 90912.
  • 15
    Hemker HC. Thrombin generation, an essential step in haemostasis and thrombosis. In: BloomAL, ForbesCD, ThomasDP, TuddenhamEGD, eds. Haemostasis and Thrombosis, Vol. 1, 3rd edn. Edinburgh: Churchill Livingstone, 1994: 47790.
  • 16
    Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 61724.
  • 17
    Hemker HC, Béguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 1348.
  • 18
    Morishima Y, Tanabe K, Terada Y, Hara T, Kunitada S. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 1997; 78: 136671.
  • 19
    Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 1995; 92: 48591.
  • 20
    Murayama N, Tanaka M, Kunitada S, Yamada H, Inoue T, Terada Y, Fujita M, Ikeda Y. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clin Pharmacol Ther 1999; 66: 25864.
  • 21
    Majerus PW, Tollfeson DM, Shuman MA. The interaction of platelets with thrombin. In: GordonJL, ed. Platelets in Biology and Pharmacology. Amsterdam: North-Holland Publishing, 1976: 24160.
  • 22
    Millis DCB, Macfarlene DE. Platelet receptors. In: GordonJL, ed. Platelets in Biology and Pharmacology. Amsterdam: North-Holland Publishing, 1976: 160202.
  • 23
    Tanabe K, Morishima Y, Shibutani T, Terada Y, Hara T, Shinohara Y, Aoyagi K, Kunitada S, Kondo T. DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model. Thromb Haemost 1999; 81: 82834.